CJC 1295 (without DAC) CND5 5mg*10vials

CJC 1295 DAC-free CND5 5mg x 10 Vials

Product Overview

CJC 1295 DAC-free CND5 is an upgraded intermediate-acting short-acting physiological growth hormone-releasing hormone analog research peptide, serving as a mid-range upgrade from the basic CND2. CND5 retains the original peptide structure without DAC modification and albumin-binding modification, supporting natural rapid metabolic clearance and standard short half-life pulsatile growth hormone release characteristic maintenance research. CND5 optimizes molecular activity and uses a standard intermediate concentration of 5mg. Compared to low-dose CND2, it supports GH and IGF-1 axis pulsatile activation efficiency significant enhancement research and more significant physiological phenotype production studies, achieving a balance between pure physiological pulsatile mimicry and efficient metabolic regulation research. CND5 is suitable for intermediate-dose gradient efficacy studies, moderate-intensity acute anabolic interventions, pulsatile body composition remodeling research, and synergistic peptide combination mechanism validation research. As a core mainstream upgrade product in the short-acting GHRH peptide class, CJC 1295 CND5 covers most mid-stage preclinical endocrinology and metabolic research scenarios.

Core Research Functions

Strong Orderly Physiologically Pulsatile GH Secretion and Moderate IGF-1 Elevation: Supports strong orderly physiologically pulsatile GH secretion triggering research and moderate IGF-1 elevation studies, supporting body natural intermittent endocrine rhythms mimicry research.

DAC Albumin Retention Absence and Rapid Metabolic Clearance: Supports DAC albumin retention absence research, excess peptides rapid metabolization and clearance studies, and hormone accumulation and continuous overstimulation related avoidance research.

Acute Anabolism Efficiency Enhancement and Fat Metabolism Activation: Supports comprehensive enhanced acute anabolism efficiency research, faster fat metabolism activation studies, and more pronounced short-cycle tissue repair effect research, resulting in intuitive and distinguishable experimental results.

Moderate-Intensity Pulsatile Lean Muscle Synthesis and Efficient Acute Fat Breakdown: Supports moderate-intensity pulsatile lean muscle synthesis mechanism exploration research, efficient acute fat breakdown and remodeling studies, moderate tissue damage repair research, and moderate threshold endocrine dose response research.

Pure Physiological Pulse Regulation and Intermediate-Dose Gradient Experiments: Supports pure physiological pulse regulation characteristic research, endocrine desensitization related studies, and minimal experimental interference research. It is suitable for intermediate-dose gradient experiments, growth hormone secretagogue synergistic validation research, and mid-term acute metabolic intervention modeling, providing high-discrimination reproducible physiological data for growth hormone and insulin-like growth factor-1 axis mechanism in-depth research.

Compared to mild low-dose CND2, CND5 supports comprehensive enhanced acute anabolism efficiency research in core research dimensions. CND5 possesses pure physiological pulse regulation characteristics, supporting endocrine desensitization related studies and minimal experimental interference research, providing high-discrimination reproducible physiological data for growth hormone and insulin-like growth factor-1 axis mechanism in-depth research.

Core Product Advantages

CND5 Intermediate Enhanced Iterative Version: An upgraded version based on CND2, optimizing molecular target activity and binding efficiency. It retains authentic non-DAC physiological pulse characteristics while supporting endocrine activation intensity significant enhancement research, bridging the research gap between low-dose baseline studies and high-dose ultra-short-acting studies.

Standard Short Half-Life Physiological Pulse: Utilizing pure unmodified peptide chains, supporting natural rapid metabolic clearance research. It achieves pure intermittent growth hormone pulse output without hormone superposition or accumulation research, supporting true physiological rhythms of the human endocrine system replication research.

5mg Balanced Medium-Acting Strength: A classic mainstream medium-concentration formulation in the CND series, addressing low-dose CND2 product insufficient phenotypic differentiation related issue research. Balancing experimental safety and efficacy, it is suitable for most routine medium-gradient studies and complex peptide synergistic studies.

High Purity and Low-Interference Regulation: Supports GHRH-GH-IGF-1 core pathway highly specific and precise targeting research. It supports stable physiological pulsatile secretion induction research, cortisol and prolactin stress hormone interference related studies, ensuring experimental variable purity and reliable mechanistic conclusion research.

Pharmaceutical-Grade Quality and Standard Packaging: Aseptic vacuum freeze-drying process supports peptide inherent activity stable retention research. Each batch undergoes rigorous HPLC purity testing and is accompanied by a complete Certificate of Analysis (COA). Aseptically packaged in 10-vial packs, suitable for medium-sized laboratory research, university key endocrinology projects, and bulk wholesale purchases.

Specifications and Quality Control

Format: Lyophilized powder, 5mg per vial. Packaging: 10 vials per pack, dust-free aseptic integrated container. Purity Testing: Full HPLC purity verification with complete Certificate of Analysis (COA).